Small Interfering RNA (siRNA) Therapeutics Market Report: Size Growth Trends & Forecast 2026–2032

Market Overview

The Small Interfering RNA (siRNA) Therapeutics Market size was valued at USD 17.55 Billion in 2025 and is expected to reach USD 54.59 Billion by 2032, expanding at a CAGR of 17.6% from 2026 to 2032. These therapies use RNA interference to silence selected disease-causing genes before they produce harmful proteins. Their expanding use in rare genetic disorders, cardiovascular conditions, cancer, ocular diseases and metabolic disorders is moving RNAi technology toward broader clinical adoption.

Request Sample Report at: https://www.maximizemarketresearch.com/request-sample/91788/

The Small Interfering RNA (siRNA) Therapeutics Market is advancing as regulatory approvals validate gene-silencing mechanisms and delivery technologies become more effective. Nanoparticles, liposomes, GalNAc conjugates and chemical modifications are improving stability, cellular uptake and tissue targeting. The principal challenge remains safe and efficient delivery beyond the liver, particularly into the brain, lungs, tumours and other complex tissues.

Key Growth Drivers Fueling the Small Interfering RNA (siRNA) Therapeutics Market

Growing demand for precision medicine: siRNA drugs can be designed to suppress specific messenger RNA targets, enabling developers to address the biological source of a disease. This precision supports treatments for inherited, metabolic and cardiovascular disorders.

Clinical and regulatory validation: The approval of patisiran established an important commercial pathway for RNAi medicines. Later therapies for acute hepatic porphyria, primary hyperoxaluria and cholesterol management have strengthened clinical confidence in the platform.

Advances in delivery systems: Lipid nanoparticles, polymeric particles and targeted conjugates protect siRNA molecules against degradation and help them enter selected cells. These systems are also expanding research beyond liver-targeted treatments.

Rising pharmaceutical R&D investment: Large pharmaceutical companies and specialist biotechnology firms are entering licensing agreements, financing clinical programs and expanding manufacturing capacity. This activity is creating pipelines across oncology, obesity, fibrosis, neurological disease and immunology.

Potential for less frequent dosing: MMR notes that certain siRNA therapies may be administered quarterly or twice yearly. Longer dosing intervals could improve treatment adherence and differentiate RNAi medicines from therapies requiring frequent administration.

Small Interfering RNA (siRNA) Therapeutics Market Segmentation By Type, Indication, Route, Application and End Use

• By type: Liposome-based systemic therapy, nanoparticle-based systemic therapy dominant in 2025, and others.
• By indication: Hereditary transthyretin-mediated amyloidosis dominant, acute hepatic porphyria, primary hyperoxaluria type 1, primary hypercholesterolemia and others.
• By route of administration: Intravenous and subcutaneous.
• By application: Oncology, genetic disorders, cardiovascular diseases, infectious diseases, metabolic disorders, neurological disorders, immunology and others.
• By end use: Hospitals and clinics, research institutions and academic laboratories, pharmaceutical and biotechnology companies, contract research organisations and others.
• Segment-share disclosure: MMR’s publicly accessible summary does not state exact numerical shares for these categories.

Nanoparticle-based systemic therapy leads because it enhances stability, controlled release and site-specific targeting while addressing degradation and weak cellular uptake. Hereditary transthyretin-mediated amyloidosis remains the leading indication because patisiran provided the first major regulatory validation of siRNA treatment. Subsequent therapies have extended RNA interference into additional rare genetic and metabolic conditions.

Regional Analysis Where Is the Small Interfering RNA (siRNA) Therapeutics Market Growing Fastest?

United States

The United States anchors North America, which dominated the industry in 2025 and is expected to retain its leadership. Its position is supported by FDA approvals, extensive clinical development and Alnylam’s USD 250 million manufacturing expansion in Massachusetts.

United Kingdom

The United Kingdom is included in MMR’s European analysis. The public report description does not provide a separate UK revenue value, market share or growth rate, so no national statistic has been estimated.

Germany

Germany is also covered within the European report scope. MMR does not disclose a standalone German market value in the publicly available summary.

Japan

Japan forms part of MMR’s Asia-Pacific assessment. No separate Japanese revenue, CAGR or market share is published in the report description.

South Korea

South Korea is included in the Asia-Pacific country coverage. The MMR public summary provides no country-specific market figure or comparative growth rate.

China

China is part of the Asia-Pacific assessment and is involved in regional RNAi research and pharmaceutical partnerships. MMR does not publish a separate Chinese market value or forecast in its public description.

India

India is included in the Asia-Pacific report scope. No standalone Indian revenue share, market value or CAGR is disclosed by MMR in the publicly accessible summary.

North America is the dominant region for the Small Interfering RNA (siRNA) Therapeutics Market. MMR does not identify a separate fastest-growing region in the public summary, while the United States is the clearest current investment hotspot because it combines regulatory leadership, clinical development and expanding manufacturing capacity.

Competitive Landscape — Leading Companies in the Small Interfering RNA (siRNA) Therapeutics Market

1. Alnylam Pharmaceuticals: Alnylam leads through approved RNAi products, a broad clinical pipeline and investment in scalable enzymatic-ligation manufacturing.
2. Novartis: Novartis participates through inclisiran and its commercial presence in cardiovascular gene-silencing treatment.
3. Novo Nordisk: Novo Nordisk strengthened its RNAi capabilities through Dicerna Pharmaceuticals and the GalXC liver-targeting delivery platform.
4. Arrowhead Pharmaceuticals: Arrowhead is developing candidates across metabolic, cardiovascular, pulmonary and obesity-related indications.
5. Silence Therapeutics: Silence Therapeutics uses its mRNAi GOLD platform to advance precision siRNA programs for targeted diseases.

Competition increasingly centres on target selection, extrahepatic delivery, dosing durability, production economics and the ability to move candidates successfully through clinical development.

Request Sample Report at: https://www.maximizemarketresearch.com/request-sample/91788/

Recent Developments and Strategic Moves

• In December 2025, Alnylam announced a USD 250 million expansion of its Norton, Massachusetts manufacturing site. The investment adds its siRELIS enzymatic-ligation platform to increase capacity and reduce production costs.
• In May 2025, AbbVie and ADARx entered a collaboration and licence-option agreement to develop next-generation siRNA therapies across neuroscience, immunology and oncology.
• GSK and Empirico entered an exclusive licensing agreement for EMP-012, a clinical-stage siRNA candidate developed through human-genetics-led target discovery.
• Boehringer Ingelheim and Ribo reached an early preclinical milestone in their partnership to develop siRNA treatments for metabolic liver disease.
• Research published in 2026 demonstrated how artificial intelligence could guide lipid design for targeted nucleic-acid delivery, indicating a path toward more predictive carrier discovery.

AI and Digital Transformation Impact on Small Interfering RNA (siRNA) Therapeutics Market

AI is changing the Small Interfering RNA (siRNA) Therapeutics Market by helping researchers assess target biology, predict silencing potency and screen sequence designs before laboratory testing. Machine-learning models can compare sequence, chemical and thermodynamic characteristics to prioritise candidates with stronger activity and fewer undesirable effects. Informatics is also becoming more important in target selection and therapeutic design.

AI-guided material discovery may accelerate the development of lipid and nonviral delivery systems. By predicting carrier properties and delivery performance, digital tools can reduce dependence on repeated empirical screening. The expected benefits include shorter optimisation cycles, improved tissue targeting and more efficient development decisions, although laboratory and clinical validation remain essential.

Future Outlook — Investment Opportunities and Emerging Trends

The future of the Small Interfering RNA (siRNA) Therapeutics Market will be shaped by extrahepatic delivery, long-duration dosing, scalable manufacturing and expansion into common chronic diseases. Attractive investment areas include nanoparticle delivery, GalNAc chemistry, neurological and pulmonary targeting, metabolic disease, oncology combinations and computational molecule design. With revenue forecast to reach USD 54.59 Billion by 2032, companies combining precise targeting, dependable safety, manufacturing efficiency and clear regulatory strategies are positioned to capture the strongest opportunities.

Related Reports

Global Urinary Catheters Market https://www.maximizemarketresearch.com/market-report/global-urinary-catheters-market/66316/

Medical Exoskeleton Market https://www.maximizemarketresearch.com/market-report/medical-exoskeleton-market/11511/

Global ENT Devices Market https://www.maximizemarketresearch.com/market-report/global-ent-devices-market/83130/

Expert Commentary

 “According to Komal Patil, Research Manager at Maximize Market Research, ‘The Small Interfering RNA (siRNA) Therapeutics Market is projected to rise from USD 17.55 Billion in 2025 to USD 54.59 Billion by 2032 at a CAGR of 17.6%. Investment will increasingly favour delivery platforms, scalable production and digitally supported molecule design that extend RNA interference beyond liver-focused rare diseases into larger cardiovascular, metabolic, neurological and oncology opportunities.’”

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

Contact Us

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com